Arcadia Biosciences "announced that it has entered into securities purchase agreements for the purchase and sale of 666,334 shares of its common stock, Series A preferred investment options to purchase up to an aggregate of 666,334 shares of common stock and Series B preferred investment options to purchase up to an aggregate of 666,334 shares of common stock at a purchase price of $9.00 per share of common stock and associated preferred investment options in a private placement priced at a premium to market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
Published first on TheFly
